Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 319 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... May 23, 2022 Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... March 30, 2022 Sisters on Opposite Sides of the Country Diagnosed with Breast Cancer... December 16, 2020 Emma Stone Motivated to Help Others After Her Mother Was Diagnosed... November 16, 2020 Load more HOT NEWS FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ Fostering Black leadership in cancer research FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial...
